Allegro Biotech
Financials
Estimates*
EUR | 2022 | 2023 |
---|---|---|
Profit | (<1m) | (<1m) |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€1.5m | Seed | ||
* | €5.5m | Seed | |
Total Funding | €7.0m |
Recent News about Allegro Biotech
EditAllegro.bio is a biomedical technology startup that operates in the fields of rheumatology and orthopedics. The company is driven by a team of scientists and patients who are committed to pushing the boundaries of medical research and development (R&D). Their mission is to design innovative solutions that can help people overcome traumatic, musculoskeletal, and degenerative diseases.
The company's primary clients are patients suffering from these conditions. Allegro.bio works closely with these individuals, considering them as core stakeholders in their business. This patient-centric approach allows the company to understand the challenges faced by these individuals and develop solutions that can effectively address their needs.
Allegro.bio operates in the biomedical technology market, a sector that is witnessing rapid growth due to the increasing prevalence of chronic diseases and the rising demand for advanced treatment options. The company's business model is centered around R&D. They invest heavily in research to develop novel biomedical technologies that can disrupt the current treatment landscape in rheumatology and orthopedics.
The company generates revenue by commercializing the technologies they develop. Once a technology is developed and approved for use, it can be sold to healthcare providers or directly to patients. The company may also generate income through partnerships with other healthcare companies or through grants for their research.
Keywords: Biomedical Technology, Rheumatology, Orthopedics, Research and Development, Patient-Centric, Musculoskeletal Diseases, Degenerative Diseases, Healthcare, Medical Research, Biotech Startup.